Market Overview
The Global Attention Deficit Hyperactivity Disorder (ADHD) Market is expected to reach at a Significant CAGR during the forecast period 2024-2031.
ADHD (Attention Deficit Hyperactivity Disorder) is one of the common neurodevelopmental disorders of childhood. It is usually first diagnosed in childhood and often lasts into adulthood. Children with ADHD can have trouble paying attention, controlling impulsive behaviors, and being overly active. ADHD has various causes, including genetic and environmental factors. According to studies, ADHD has a high heritability rate of 70% to 80%, indicating a substantial genetic component.
The global attention deficit hyperactivity disorder (ADHD) market is driven by the development of innovative therapies. For instance, in May 2024, The FDA approved Tris Pharma's reformulation of clonidine hydrochloride for the treatment of attention deficit hyperactivity disorder in pediatric patients aged six and older. The once-daily medication will be sold under the brand name Onyda XR.
Market Summary
| Metrics | Details |
| CAGR | Prominent Growth |
| Market Size Available for Years | 2022-2031 |
| Estimation Forecast Period | 2024-2031 |
| Revenue Units | Value (US$ Mn) |
| Segments Covered | Drug Type |
| Age Group | |
| Distribution Channel | |
| Regions Covered | North America, Europe, Asia-Pacific, South America, and Middle East & Africa |
For more details on this report – Request for Sample
Market Dynamics: Drivers & Restraints
Increasing drug approvals
The increasing drug approvals is expected to be a significant factor in the growth of the global attention deficit hyperactivity disorder (ADHD) market. Recent advances in drug development and treatment methods have resulted in a greater spectrum of authorized ADHD drugs. Innovative formulations, including long-acting stimulants and non-stimulant choices, respond to different patient demands and preferences, hence promoting further approvals.
For instance, in September 2023, Amneal received FDA approval for lisdexamfetamine dimesylate capsules to treat ADHD. lisdexamfetamine dimesylate capsules are a generic version of Vyvanse. Research and development efforts in the ADHD field have introduced new medicines, formulations, and treatment strategies. Pharmaceutical businesses and research organizations are actively investing in developing novel drugs, extended-release formulations, and alternative routes of administration. Pharmaceutical companies invest in research and development to discover and develop new drugs for ADHD.
Adverse Side Effects of Treatment Drugs
Medications used in the global ADHD market, such as methylphenidate (e.g., Ritalin, Concerta), amphetamine-based drugs (e.g., Adderall, Vyvanse), and atomoxetine (e.g., Strattera) have adverse effects. However, their occurrence and severity vary between individuals. Common adverse effects include loss of appetite, insomnia, gastrointestinal difficulties, headaches, elevated heart rate and blood pressure, mood changes, tics, and probable growth inhibition in youngsters. Thus owing to the above factors, the market is expected to restrain over the forecast period.
Market Segment Analysis
The global attention deficit hyperactivity disorder (ADHD) market is segmented based on drug type, age group, distribution channel, and region
Drug Type:
Stimulant segment is expected to dominate the global attention deficit hyperactivity disorder (ADHD) market share
The stimulant segment is expected to dominate the global attention deficit hyperactivity disorder (ADHD) market share due to its effectiveness in managing attention deficit hyperactivity disorder (ADHD). Stimulant medications segment such as methylphenidate and amphetamines, will see a significant increase in the market due to their widespread use and demonstrated effectiveness in addressing ADHD symptoms such as short attention span, impulsive behavior, and hyperactivity.
For instance, focalin is a form of dexmethylphenidate, which is the active component of racemic methylphenidate. It is available in both immediate-release and extended-release formulations. Also, the extended-release formulations, such as Concerta, provide a longer duration of action, allowing for once-daily dosing. These medications aim to improve attention, focus, impulse control, and overall executive functions in individuals with ADHD. The choice between methylphenidate and amphetamine-based medications, as well as the specific formulation, depends on factors such as individual response. Thus, owing to the above factors, it is expected to hold the largest segment.
Non-stimulant segment is the fastest growing segment in the global attention deficit hyperactivity disorder (ADHD) share.
Non-stimulant segment is the fastest growing segment in the global attention deficit hyperactivity disorder (ADHD) market. The rapid expansion of the non-stimulant segment in the worldwide ADHD market is being driven by increased clinician and patient acceptance, better pharmacological profiles with fewer side effects, expanding patient demographics, and ongoing research initiatives. As understanding of the different needs of ADHD patients grows, non-stimulant medicines are expected to play an increasingly important part in comprehensive ADHD management regimens.
Age Group:
Pediatric segment is expected to dominate the global attention deficit hyperactivity disorder (ADHD) market share
The pediatric segment is expected to hold the dominant position in the global attention deficit hyperactivity disorder (ADHD) market share. This is due to the increasing incidence of attention deficit hyperactivity disorder. The high prevalence of attention deficit hyperactivity disorder increases the demand for this market.
For instance, according to an article published by the National Library of Medicine titled "ADHD Diagnostic Trends: Increased Recognition or Overdiagnosis" shows that the prevalence of ADHD in the US is substantially higher, impacting about 8.7% or 5.3 million children.
Adults segment is the fastest growing segment in the global attention deficit hyperactivity disorder (ADHD) market share
The rapid growth of the adult segment in the global ADHD market can be attributed to increased recognition of adult ADHD as a legitimate condition, shifting societal attitudes toward mental health, advancements in adult-specific treatment options, and rising healthcare expenditures for mental health services.
Market Geographical Share
North America is expected to hold a significant position in the global attention deficit hyperactivity disorder (ADHD) market share
North America is expected to hold a significant position in the market share during the forecast period. High diagnostic rates, growing prevalence, a developed healthcare infrastructure, and rising healthcare costs are among the primary factors. High diagnostic rates, growing prevalence, a developed healthcare infrastructure, and rising healthcare costs are among the primary factors. The pharmaceutical sector plays a major role in the ADHD market. Stimulant medications, such as those containing methylphenidate or amphetamine, are commonly prescribed for ADHD management. Non-stimulant medications, like atomoxetine, are also widely used.
Ongoing research and development contribute to innovations in ADHD treatment approaches. This can include the development of new medications, formulations, and delivery methods, as well as advancements in non-pharmacological interventions in the North America region. For instance, in July 2023, Mentavi Health introduced a transformative series of developments poised to usher in a new era for the company. These advancements include the formation of a new corporate entity and the securing of a Series AA investment. The formation of the new corporate entity is a strategic step taken by Mentavi Health and ADHD Online to enhance operations and open doors for further expansion.
Asia Pacific is growing at the fastest pace in the global attention deficit hyperactivity disorder (ADHD) market
Asia Pacific is experiencing the fastest growth in the global attention deficit hyperactivity disorder (ADHD) market. The rapid expansion of the ADHD market in the Asia Pacific is being driven by growing awareness of the condition, advances in treatment choices, improvements in healthcare infrastructure, and shifting socioeconomic dynamics. As these characteristics continue to converge, they will likely boost the accessibility and effectiveness of ADHD management techniques across the region.
Market Segmentation
By Drug Type
- Stimulant
- Methylphenidate
- Amphetamine
- Dextroamphetamine
- Dexmethylphenidate
- Non-stimulant
- Atomoxetine
- Bupropion
- Guanfacine
- Others
By Age Group
- Pediatric
- Adults
By Distribution Channel
- Retail Pharmacies
- Hospital Pharmacies
- Online Pharmacies
By End-User
- Hospitals
- Specialty Clinics
- Others
By Region
- North America
- U.S.
- Canada
- Mexico
- Europe
- Germany
- U.K.
- France
- Spain
- Italy
- Rest of Europe
- South America
- Brazil
- Argentina
- Rest of South America
- Asia-Pacific
- China
- India
- Japan
- South Korea
- Rest of Asia-Pacific
- Middle East and Africa
Market Companies
The major global players in the global attention deficit hyperactivity disorder (ADHD) market include Pfizer Inc., Teva Pharmaceutical Industries Ltd, Novartis AG, Eli Lilly and Company, Johnson & Johnson, Lupin Ltd, Mallinckrodt Plc, Hisamitsu Pharmaceutical Co.Inc., Purdue Pharma L.P., Camber Pharmaceuticals Inc. among others.
Emerging Players
Cingulate Therapeutics, EndeavorRx, and Tris Pharma among others.
Key Developments
In August 2023, Mallinckrodt received U.S. FDA approval for Lisdexamfetamine Dimesylate Capsules and launched a product used to treat Attention-Deficit/Hyperactivity Disorder (ADHD).
Why Purchase the Report?
- To visualize the global attention deficit hyperactivity disorder (ADHD) market segmentation based on drug type, age group, distribution channel, and region as well as understand key commercial assets and players.
- Identify commercial opportunities by analyzing trends and co-development.
- Excel data sheet with numerous data points of global attention deficit hyperactivity disorder (ADHD) market-level with all segments.
- PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
- Product mapping available as Excel consisting of key products of all the major players.
The global attention deficit hyperactivity disorder (ADHD) market report would provide approximately 53 tables, 47 figures, and 176 pages.
Target Audience 2024
- Manufacturers/ Buyers
- Industry Investors/Investment Bankers
- Research Professionals
- Emerging Companies
